Loading...

Tandem Diabetes Care

DB:TD5A
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TD5A
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • Tandem Diabetes Care has significant price volatility in the past 3 months.
TD5A Share Price and Events
7 Day Returns
6.6%
DB:TD5A
3.2%
DE Medical Equipment
-0.2%
DE Market
1 Year Returns
472.1%
DB:TD5A
14.6%
DE Medical Equipment
-10.3%
DE Market
TD5A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tandem Diabetes Care (TD5A) 6.6% 25.6% 32.7% 472.1% -3.3% -49.6%
DE Medical Equipment 3.2% 3.7% 7.8% 14.6% 109.1% 242%
DE Market -0.2% -2.4% 4% -10.3% 11.2% 10.8%
1 Year Return vs Industry and Market
  • TD5A outperformed the Medical Equipment industry which returned 14.6% over the past year.
  • TD5A outperformed the Market in Germany which returned -10.3% over the past year.
Price Volatility
TD5A
Industry
5yr Volatility vs Market

Value

 Is Tandem Diabetes Care undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Tandem Diabetes Care to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Tandem Diabetes Care.

DB:TD5A Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 13 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:TD5A
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.9
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.895 (1 + (1- 21%) (0.37%))
0.932
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.932 * 5.96%)
5.78%

Discounted Cash Flow Calculation for DB:TD5A using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Tandem Diabetes Care is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:TD5A DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.78%)
2019 3.26 Analyst x3 3.08
2020 36.47 Analyst x4 32.59
2021 76.36 Analyst x3 64.51
2022 154.00 Analyst x1 123.00
2023 223.80 Analyst x1 168.98
2024 281.88 Est @ 25.95% 201.21
2025 333.28 Est @ 18.23% 224.89
2026 376.04 Est @ 12.83% 239.89
2027 410.08 Est @ 9.05% 247.31
2028 436.34 Est @ 6.4% 248.76
Present value of next 10 years cash flows $1,554.22
DB:TD5A DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $436.34 × (1 + 0.23%) ÷ (5.78% – 0.23%)
$7,877.00
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $7,877.00 ÷ (1 + 5.78%)10
$4,490.79
DB:TD5A Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,554.22 + $4,490.79
$6,045.01
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,045.01 / 58.07
$104.1
DB:TD5A Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:TD5A represents 0.88892x of NasdaqGM:TNDM
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88892x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 104.10 x 0.88892
€92.54
Value per share (EUR) From above. €92.54
Current discount Discount to share price of €58.98
= -1 x (€58.98 - €92.54) / €92.54
36.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Tandem Diabetes Care is available for.
Intrinsic value
36%
Share price is €58.98 vs Future cash flow value of €92.54
Current Discount Checks
For Tandem Diabetes Care to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Tandem Diabetes Care's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Tandem Diabetes Care's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tandem Diabetes Care's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tandem Diabetes Care's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:TD5A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.94
NasdaqGM:TNDM Share Price ** NasdaqGM (2019-05-20) in USD $66.35
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 36.34x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tandem Diabetes Care.

DB:TD5A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:TNDM Share Price ÷ EPS (both in USD)

= 66.35 ÷ -1.94

-34.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tandem Diabetes Care is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Tandem Diabetes Care is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Tandem Diabetes Care's expected growth come at a high price?
Raw Data
DB:TD5A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -34.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts
63.4%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 3.08x
Germany Market PEG Ratio Median Figure of 273 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tandem Diabetes Care, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tandem Diabetes Care's assets?
Raw Data
DB:TD5A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.09
NasdaqGM:TNDM Share Price * NasdaqGM (2019-05-20) in USD $66.35
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.25x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:TD5A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:TNDM Share Price ÷ Book Value per Share (both in USD)

= 66.35 ÷ 2.09

31.8x

* Primary Listing of Tandem Diabetes Care.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tandem Diabetes Care is overvalued based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Tandem Diabetes Care's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Tandem Diabetes Care has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Tandem Diabetes Care expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tandem Diabetes Care expected to grow at an attractive rate?
  • Tandem Diabetes Care's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Tandem Diabetes Care's earnings growth is expected to exceed the Germany market average.
  • Tandem Diabetes Care's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:TD5A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:TD5A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 13 Analysts 63.4%
DB:TD5A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 13 Analysts 19.8%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:TD5A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:TD5A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 666 237 105 2
2022-12-31 571 166 51 4
2021-12-31 470 85 4 7
2020-12-31 388 50 -18 13
2019-12-31 312 17 -45 13
DB:TD5A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 223 0 -113
2018-12-31 184 -8 -123
2018-09-30 148 -34 -138
2018-06-30 129 -50 -119
2018-03-31 116 -58 -82
2017-12-31 108 -66 -73
2017-09-30 96 -68 -76
2017-06-30 82 -67 -90
2017-03-31 83 -66 -87
2016-12-31 84 -61 -83
2016-09-30 84 -58 -81
2016-06-30 88 -54 -70

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Tandem Diabetes Care's earnings are expected to grow significantly at over 20% yearly.
  • Tandem Diabetes Care's revenue is expected to grow by 19.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:TD5A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below

All data from Tandem Diabetes Care Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TD5A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.73 2.65 0.80 2.00
2022-12-31 0.84 1.74 -0.07 2.00
2021-12-31 0.07 0.36 -0.35 4.00
2020-12-31 -0.25 0.37 -0.59 11.00
2019-12-31 -0.78 -0.33 -1.03 11.00
DB:TD5A Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.94
2018-12-31 -2.55
2018-09-30 -3.82
2018-06-30 -5.10
2018-03-31 -8.74
2017-12-31 -12.86
2017-09-30 -18.54
2017-06-30 -25.15
2017-03-31 -28.01
2016-12-31 -27.30
2016-09-30 -26.55
2016-06-30 -23.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tandem Diabetes Care will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Tandem Diabetes Care's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tandem Diabetes Care has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Tandem Diabetes Care performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tandem Diabetes Care's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tandem Diabetes Care does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Tandem Diabetes Care's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tandem Diabetes Care's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Tandem Diabetes Care's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tandem Diabetes Care Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:TD5A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 222.58 -112.91 119.27 32.64
2018-12-31 183.87 -122.61 105.23 29.23
2018-09-30 147.96 -137.71 94.35 26.18
2018-06-30 128.70 -119.49 84.97 23.10
2018-03-31 115.90 -81.93 84.44 21.51
2017-12-31 107.60 -73.03 86.38 20.66
2017-09-30 96.22 -76.45 84.14 19.26
2017-06-30 81.51 -90.23 84.70 20.50
2017-03-31 83.17 -86.76 83.69 19.77
2016-12-31 84.25 -83.45 82.83 18.81
2016-09-30 84.46 -80.71 84.31 18.60
2016-06-30 87.88 -70.49 82.75 17.54
2016-03-31 80.60 -71.69 81.26 17.27
2015-12-31 72.85 -72.42 78.62 16.96
2015-09-30 61.62 -78.79 78.19 16.75
2015-06-30 59.42 -79.11 77.97 16.16
2015-03-31 53.97 -78.77 76.44 15.99
2014-12-31 49.72 -79.52 75.12 15.79
2014-09-30 42.08 -84.67 69.31 15.22
2014-06-30 36.34 -77.83 62.42 13.36
2014-03-31 31.61 -73.94 55.68 12.42
2013-12-31 29.01 -63.14 44.52 11.08
2013-09-30 21.02 -48.08 36.18 9.72
2013-06-30 13.46 -42.53 30.64 9.18
2013-03-31 7.93 -35.70 24.44 8.88
2012-12-31 2.48 -33.02 22.69 9.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tandem Diabetes Care has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Tandem Diabetes Care has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tandem Diabetes Care improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Tandem Diabetes Care's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tandem Diabetes Care has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Tandem Diabetes Care's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tandem Diabetes Care's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tandem Diabetes Care is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Tandem Diabetes Care's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tandem Diabetes Care's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 12.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tandem Diabetes Care Company Filings, last reported 1 month ago.

DB:TD5A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 120.96 14.39 125.60
2018-12-31 131.28 0.00 129.03
2018-09-30 115.43 0.00 113.58
2018-06-30 26.01 77.10 86.51
2018-03-31 11.85 76.41 71.88
2017-12-31 -29.15 76.54 14.18
2017-09-30 -27.96 75.60 12.54
2017-06-30 -18.28 74.68 27.79
2017-03-31 -1.87 73.76 44.01
2016-12-31 -5.93 78.96 53.54
2016-09-30 5.20 44.68 34.08
2016-06-30 32.07 44.40 54.32
2016-03-31 45.94 44.11 68.43
2015-12-31 63.47 29.28 71.11
2015-09-30 71.23 29.50 81.75
2015-06-30 87.75 29.48 97.75
2015-03-31 102.25 29.46 116.38
2014-12-31 54.57 29.44 67.28
2014-09-30 67.48 29.42 79.88
2014-06-30 83.55 29.39 94.31
2014-03-31 97.26 29.44 110.77
2013-12-31 115.54 29.40 129.48
2013-09-30 2.58 29.35 15.55
2013-06-30 9.15 29.29 30.13
2013-03-31 18.59 4.20 17.16
2012-12-31 18.59 4.20 17.16
  • Tandem Diabetes Care's level of debt (11.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (30.3% vs 11.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Tandem Diabetes Care has sufficient cash runway for more than 3 years based on current free cash flow.
  • Tandem Diabetes Care has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -32.3% each year.
X
Financial health checks
We assess Tandem Diabetes Care's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tandem Diabetes Care has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Tandem Diabetes Care's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tandem Diabetes Care dividends. Estimated to be 0% next year.
If you bought €2,000 of Tandem Diabetes Care shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tandem Diabetes Care's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tandem Diabetes Care's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:TD5A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 13 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:TD5A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tandem Diabetes Care has not reported any payouts.
  • Unable to verify if Tandem Diabetes Care's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tandem Diabetes Care's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tandem Diabetes Care has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Tandem Diabetes Care's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Tandem Diabetes Care's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tandem Diabetes Care afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tandem Diabetes Care has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Tandem Diabetes Care's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Sheridan
COMPENSATION $1,937,417
AGE 63
TENURE AS CEO 0.2 years
CEO Bio

Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 2013 until March 01, 2019. Mr. Sheridan served as Chief Operating Officer at Rapiscan Systems, Inc. from March 2012 to February 2013. Mr. Sheridan served as an Executive Vice President of Research and Development and Operations of Volcano Corp. from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation and led the development and manufacturing efforts for scintillator/photodiode detector system. Prior to joining Digirad Corp., from October 1983 to March 1998, Mr. Sheridan held various positions, including Director of Operations, at Analog Devices Inc., a semiconductor company that develops, manufacturers and markets high performance integrated circuits used in signal-processing applications. He holds a B.S. Degree in Chemistry from the University of West Florida and an M.B.A. from Boston University.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Tandem Diabetes Care management team in years:

1.8
Average Tenure
49
Average Age
  • The average tenure for the Tandem Diabetes Care management team is less than 2 years, this suggests a new team.
Management Team

Kim Blickenstaff

TITLE
Executive Chairman of the Board
COMPENSATION
$3M
AGE
66
TENURE
0.2 yrs

John Sheridan

TITLE
President & CEO
COMPENSATION
$2M
AGE
63
TENURE
0.2 yrs

Leigh Vosseller

TITLE
Executive VP
COMPENSATION
$2M
AGE
45
TENURE
6.3 yrs

David Berger

TITLE
Executive VP
COMPENSATION
$2M
AGE
48
TENURE
5.8 yrs

Brian Hansen

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$2M
AGE
50
TENURE
3.3 yrs

Manuel Jaime

TITLE
Senior Vice President of Technology & Digital Health
TENURE
0.3 yrs

Susan Morrison

TITLE
Executive VP & Chief Administrative Officer
COMPENSATION
$3M
AGE
39
TENURE
5.7 yrs

Tom Fox

TITLE
Vice President of Human Resources
TENURE
1.8 yrs

Jim Leal

TITLE
Senior Vice President of Operations
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Tandem Diabetes Care board of directors in years:

5.8
Average Tenure
62
Average Age
  • The tenure for the Tandem Diabetes Care board of directors is about average.
Board of Directors

Doug Roeder

TITLE
Independent Director
COMPENSATION
$588K
AGE
47
TENURE
10 yrs

Kim Blickenstaff

TITLE
Executive Chairman of the Board
COMPENSATION
$3M
AGE
66
TENURE
0.2 yrs

Fred Cohen

TITLE
Independent Director
COMPENSATION
$575K
AGE
62
TENURE
5.9 yrs

Christopher Twomey

TITLE
Independent Director
COMPENSATION
$589K
AGE
59
TENURE
5.8 yrs

Dick Allen

TITLE
Lead Independent Director
COMPENSATION
$618K
AGE
74
TENURE
0.2 yrs

Ted Greene

TITLE
Independent Director
COMPENSATION
$572K
AGE
75
TENURE
11.3 yrs

Ed Cahill

TITLE
Independent Director
COMPENSATION
$574K
AGE
65
TENURE
10 yrs

Rick Valencia

TITLE
Director
COMPENSATION
$846K
AGE
56
TENURE
0.9 yrs

Beckie Robertson

TITLE
Independent Director
AGE
57
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • Tandem Diabetes Care insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. May 19 Sell Cornerstone Ventures Inc. Company 02. May 19 02. May 19 -4,000 €54.89 €-219,557
03. May 19 Sell Dick Allen Individual 02. May 19 02. May 19 -13,000 €54.86 €-713,136
13. Mar 19 Sell Kim Blickenstaff Individual 11. Mar 19 11. Mar 19 -200,000 €58.47 €-11,566,691
11. Mar 19 Sell Cornerstone Ventures Inc. Company 08. Mar 19 08. Mar 19 -4,103 €56.22 €-229,246
11. Mar 19 Sell Dick Allen Individual 08. Mar 19 08. Mar 19 -13,436 €56.23 €-746,987
01. Mar 19 Sell Howard Greene Individual 28. Feb 19 28. Feb 19 -10,000 €58.14 €-574,176
03. Jan 19 Sell John Sheridan Individual 31. Dec 18 31. Dec 18 -788 €33.03 €-26,025
07. Nov 18 Sell Cornerstone Ventures Inc. Company 05. Nov 18 05. Nov 18 -3,898 €33.11 €-129,050
07. Nov 18 Sell Dick Allen Individual 05. Nov 18 05. Nov 18 -11,324 €33.42 €-378,449
07. Nov 18 Buy Richard Valencia Individual 05. Nov 18 05. Nov 18 1,300 €33.11 €43,039
07. Nov 18 Sell Howard Greene Individual 06. Nov 18 06. Nov 18 -11,787 €32.01 €-377,273
07. Nov 18 Sell Kim Blickenstaff Individual 06. Nov 18 07. Nov 18 -198,000 €32.26 €-6,386,759
03. Aug 18 Buy Richard Valencia Individual 03. Aug 18 03. Aug 18 1,754 €24.57 €43,096
X
Management checks
We assess Tandem Diabetes Care's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tandem Diabetes Care has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump’s software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; and various pump accessories. Its products in development include t:slim X2 with control IQ technology; t:sport insulin delivery system; and connected (mobile) health offerings. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

Details
Name: Tandem Diabetes Care, Inc.
TD5A
Exchange: DB
Founded: 2006
$3,489,148,035
58,067,241
Website: http://www.tandemdiabetes.com
Address: Tandem Diabetes Care, Inc.
11075 Roselle Street,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM TNDM Common Stock Nasdaq Global Market US USD 14. Nov 2013
DB TD5A Common Stock Deutsche Boerse AG DE EUR 14. Nov 2013
LSE 0M0F Common Stock London Stock Exchange GB USD 14. Nov 2013
Number of employees
Current staff
Staff numbers
653
Tandem Diabetes Care employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 22:01
End of day share price update: 2019/05/20 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/04/30
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.